Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor

Fang Wang, W. Eric Knabe, Liwei Li, Inha Jo, Timmy Mani, Hartmut Roehm, Kyungsoo Oh, Jing Li, May Khanna, Samy Meroueh

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The urokinase receptor (uPAR) serves as a docking site to the serine protease urokinase-type plasminogen activator (uPA) to promote extracellular matrix (ECM) degradation and tumor invasion and metastasis. Previously, we had reported a small molecule inhibitor of the uPAR·uPA interaction that emerged from structure-based virtual screening. Here, we measure the affinity of a large number of derivatives from commercial sources. Synthesis of additional compounds was carried out to probe the role of various groups on the parent compound. Extensive structure-based computational studies suggested a binding mode for these compounds that led to a structure-activity relationship study. Cellular studies in non-small cell lung cancer (NSCLC) cell lines that include A549, H460 and H1299 showed that compounds blocked invasion, migration and adhesion. The effects on invasion of active compounds were consistent with their inhibition of uPA and MMP proteolytic activity. These compounds showed weak cytotoxicity consistent with the confined role of uPAR to metastasis.

Original languageEnglish
Pages (from-to)4760-4773
Number of pages14
JournalBioorganic and Medicinal Chemistry
Volume20
Issue number15
DOIs
StatePublished - Aug 1 2012

Fingerprint

Urokinase-Type Plasminogen Activator
Cellular Structures
Molecules
Cells
Neoplasm Metastasis
Lead compounds
Serine Proteases
Structure-Activity Relationship
Cytotoxicity
Matrix Metalloproteinases
Non-Small Cell Lung Carcinoma
Extracellular Matrix
Tumors
Screening
Adhesion
Derivatives
Degradation
Neoplasms

Keywords

  • Lung cancer
  • Metastasis
  • Protein-protein interaction
  • Small molecule inhibitors
  • Structure-activity relationship
  • Structure-based drug design
  • Synthesis
  • Urokinase receptor
  • Virtual screening

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor. / Wang, Fang; Eric Knabe, W.; Li, Liwei; Jo, Inha; Mani, Timmy; Roehm, Hartmut; Oh, Kyungsoo; Li, Jing; Khanna, May; Meroueh, Samy.

In: Bioorganic and Medicinal Chemistry, Vol. 20, No. 15, 01.08.2012, p. 4760-4773.

Research output: Contribution to journalArticle

Wang, Fang ; Eric Knabe, W. ; Li, Liwei ; Jo, Inha ; Mani, Timmy ; Roehm, Hartmut ; Oh, Kyungsoo ; Li, Jing ; Khanna, May ; Meroueh, Samy. / Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor. In: Bioorganic and Medicinal Chemistry. 2012 ; Vol. 20, No. 15. pp. 4760-4773.
@article{710e07a2a729404bbbaa041a822f7f87,
title = "Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor",
abstract = "The urokinase receptor (uPAR) serves as a docking site to the serine protease urokinase-type plasminogen activator (uPA) to promote extracellular matrix (ECM) degradation and tumor invasion and metastasis. Previously, we had reported a small molecule inhibitor of the uPAR·uPA interaction that emerged from structure-based virtual screening. Here, we measure the affinity of a large number of derivatives from commercial sources. Synthesis of additional compounds was carried out to probe the role of various groups on the parent compound. Extensive structure-based computational studies suggested a binding mode for these compounds that led to a structure-activity relationship study. Cellular studies in non-small cell lung cancer (NSCLC) cell lines that include A549, H460 and H1299 showed that compounds blocked invasion, migration and adhesion. The effects on invasion of active compounds were consistent with their inhibition of uPA and MMP proteolytic activity. These compounds showed weak cytotoxicity consistent with the confined role of uPAR to metastasis.",
keywords = "Lung cancer, Metastasis, Protein-protein interaction, Small molecule inhibitors, Structure-activity relationship, Structure-based drug design, Synthesis, Urokinase receptor, Virtual screening",
author = "Fang Wang and {Eric Knabe}, W. and Liwei Li and Inha Jo and Timmy Mani and Hartmut Roehm and Kyungsoo Oh and Jing Li and May Khanna and Samy Meroueh",
year = "2012",
month = "8",
day = "1",
doi = "10.1016/j.bmc.2012.06.002",
language = "English",
volume = "20",
pages = "4760--4773",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "15",

}

TY - JOUR

T1 - Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor

AU - Wang, Fang

AU - Eric Knabe, W.

AU - Li, Liwei

AU - Jo, Inha

AU - Mani, Timmy

AU - Roehm, Hartmut

AU - Oh, Kyungsoo

AU - Li, Jing

AU - Khanna, May

AU - Meroueh, Samy

PY - 2012/8/1

Y1 - 2012/8/1

N2 - The urokinase receptor (uPAR) serves as a docking site to the serine protease urokinase-type plasminogen activator (uPA) to promote extracellular matrix (ECM) degradation and tumor invasion and metastasis. Previously, we had reported a small molecule inhibitor of the uPAR·uPA interaction that emerged from structure-based virtual screening. Here, we measure the affinity of a large number of derivatives from commercial sources. Synthesis of additional compounds was carried out to probe the role of various groups on the parent compound. Extensive structure-based computational studies suggested a binding mode for these compounds that led to a structure-activity relationship study. Cellular studies in non-small cell lung cancer (NSCLC) cell lines that include A549, H460 and H1299 showed that compounds blocked invasion, migration and adhesion. The effects on invasion of active compounds were consistent with their inhibition of uPA and MMP proteolytic activity. These compounds showed weak cytotoxicity consistent with the confined role of uPAR to metastasis.

AB - The urokinase receptor (uPAR) serves as a docking site to the serine protease urokinase-type plasminogen activator (uPA) to promote extracellular matrix (ECM) degradation and tumor invasion and metastasis. Previously, we had reported a small molecule inhibitor of the uPAR·uPA interaction that emerged from structure-based virtual screening. Here, we measure the affinity of a large number of derivatives from commercial sources. Synthesis of additional compounds was carried out to probe the role of various groups on the parent compound. Extensive structure-based computational studies suggested a binding mode for these compounds that led to a structure-activity relationship study. Cellular studies in non-small cell lung cancer (NSCLC) cell lines that include A549, H460 and H1299 showed that compounds blocked invasion, migration and adhesion. The effects on invasion of active compounds were consistent with their inhibition of uPA and MMP proteolytic activity. These compounds showed weak cytotoxicity consistent with the confined role of uPAR to metastasis.

KW - Lung cancer

KW - Metastasis

KW - Protein-protein interaction

KW - Small molecule inhibitors

KW - Structure-activity relationship

KW - Structure-based drug design

KW - Synthesis

KW - Urokinase receptor

KW - Virtual screening

UR - http://www.scopus.com/inward/record.url?scp=84863987316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863987316&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2012.06.002

DO - 10.1016/j.bmc.2012.06.002

M3 - Article

VL - 20

SP - 4760

EP - 4773

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 15

ER -